TNFRSF14 and neoplasm: Our findings support the notion that HVEM expression on tumor cells provides them with a survival advantage to resist the anti-tumor response mediated by NK cells and T cells putting HVEM in the spotlight of a potential therapeutic target for immune intervention in tumors of hematological origin.